Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAD regimen in newly diagnosed circulating plasma cell-positive multiple myeloma
ChiCTR1900024271Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bortezomib, pegylated liposomal doxorubicin and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started Aug 2019; status: recruiting.
02
Drugs
bortezomibpegylated liposomal doxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900024271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024271.